[S02DA03, antipyrine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Olmesartan.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Olmesartan.]
[J01EC01, sulfamethoxazole, Olmesartan may decrease the excretion rate of Sulfamethoxazole which could result in a higher serum level.]
[M04AB02, sulfinpyrazone, Olmesartan may decrease the excretion rate of Sulfinpyrazone which could result in a higher serum level.]
[M01AB02, sulindac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Sulindac.]
[M01AX04, apazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Azapropazone.]
[L02BA01, tamoxifen, The risk or severity of liver damage can be increased when Olmesartan is combined with Tamoxifen.]
[R03CC03, terbutaline, Terbutaline may decrease the antihypertensive activities of Olmesartan.]
[N05AE05, lurasidone, Lurasidone may decrease the antihypertensive activities of Olmesartan.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Olmesartan is combined with Apomorphine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Olmesartan is combined with Thalidomide.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Olmesartan.]
[N05AB08, thioproperazine, Thioproperazine may decrease the antihypertensive activities of Olmesartan.]
[N05AC02, thioridazine, Thioridazine may decrease the antihypertensive activities of Olmesartan.]
[G04BE06, moxisylyte, Moxisylyte may decrease the antihypertensive activities of Olmesartan.]
[S01ED01, timolol, Olmesartan may increase the hypotensive activities of Timolol.]
[P01AB02, tinidazole, Olmesartan may decrease the excretion rate of Tinidazole which could result in a higher serum level.]
[M02AX02, tolazoline, Tolazoline may decrease the antihypertensive activities of Olmesartan.]
[M02AA21, tolmetin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Tolmetin.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypotensive activities of Olmesartan.]
[N06AX05, trazodone, Trazodone may decrease the antihypertensive activities of Olmesartan.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Olmesartan is combined with Tretinoin.]
[C03DB02, triamterene, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Triamterene.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Olmesartan can be increased when used in combination with Trichlormethiazide.]
[N05AB06, trifluoperazine, Trifluoperazine may decrease the antihypertensive activities of Olmesartan.]
[A03AA05, trimebutine, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Trimebutine.]
[S01ED04, metipranolol, Olmesartan may increase the hypotensive activities of Metipranolol.]
[N03AC02, trimethadione, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Trimethadione.]
[C02BA01, trimethaphan, Olmesartan may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Olmesartan.]
[N06AA06, trimipramine, Trimipramine may decrease the antihypertensive activities of Olmesartan.]
[N06AX24, vilazodone, Vilazodone may decrease the antihypertensive activities of Olmesartan.]
[C09CA09, azilsartan medoxomil, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Olmesartan is combined with Azilsartan medoxomil.]
[R03AC18, indacaterol, Indacaterol may decrease the antihypertensive activities of Olmesartan.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Olmesartan is combined with Verapamil.]
[L01CA01, vinblastine, Olmesartan may decrease the excretion rate of Vinblastine which could result in a higher serum level.]
[C04AX07, vincamine, Olmesartan may increase the hypotensive activities of Vincamine.]
[L01CA02, vincristine, Olmesartan may decrease the excretion rate of Vincristine which could result in a higher serum level.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Olmesartan.]
[C03BA10, xipamide, Olmesartan may increase the hypotensive activities of Xipamide.]
[N05AF05, zuclopenthixol, Zuclopenthixol may decrease the antihypertensive activities of Olmesartan.]
[J05AE02, indinavir, Olmesartan may decrease the excretion rate of Indinavir which could result in a higher serum level.]
[N05AE04, ziprasidone, Ziprasidone may increase the antihypertensive activities of Olmesartan.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Drospirenone.]
[N02BA01, aspirin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Acetylsalicylic acid.]
[C07AB03, atenolol, Olmesartan may decrease the excretion rate of Atenolol which could result in a higher serum level.]
[L01FA01, rituximab, Olmesartan may increase the hypotensive activities of Rituximab.]
[S01FA01, atropine, Olmesartan may decrease the excretion rate of Atropine which could result in a higher serum level.]
[G04BE10, avanafil, Olmesartan may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Olmesartan.]
[G04BD12, mirabegron, Mirabegron may decrease the antihypertensive activities of Olmesartan.]
[C01CA18, octopamine, Octopamine may decrease the antihypertensive activities of Olmesartan.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Olmesartan.]
[J05AE04, nelfinavir, Olmesartan may decrease the excretion rate of Nelfinavir which could result in a higher serum level.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Olmesartan.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Olmesartan.]
[C08CA13, lercanidipine, Olmesartan may increase the hypotensive activities of Lercanidipine.]
[N02CC03, zolmitriptan, Zolmitriptan may decrease the antihypertensive activities of Olmesartan.]
[N01AA01, ethyl ether, Diethyl ether may decrease the antihypertensive activities of Olmesartan.]
[G04BE03, sildenafil, Sildenafil may increase the antihypertensive activities of Olmesartan.]
[C04AX11, bencyclane, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Bencyclane.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Olmesartan can be increased when used in combination with Bendroflumethiazide.]
[N02BA10, benorilate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of hypotension, hyperkalemia, and reduced intravascular volume can be increased when Canagliflozin is combined with Olmesartan.]
[M04AB03, benzbromarone, Olmesartan may decrease the excretion rate of Benzbromarone which could result in a higher serum level.]
[M01AH01, celecoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Celecoxib.]
[N02CC02, naratriptan, Naratriptan may decrease the antihypertensive activities of Olmesartan.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Olmesartan resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R02AX03, benzydamine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Benzydamine.]
[C08EA02, bepridil, Olmesartan may increase the hypotensive activities of Bepridil.]
[C02KX05, riociguat, Olmesartan may increase the hypotensive activities of Riociguat.]
[A05AA03, cholic acid, Olmesartan may decrease the excretion rate of Cholic Acid which could result in a higher serum level.]
[C02KX04, macitentan, Olmesartan may increase the hypotensive activities of Macitentan.]
[N06AX26, vortioxetine, Vortioxetine may decrease the antihypertensive activities of Olmesartan.]
[J05AP05, simeprevir, The risk or severity of liver damage can be increased when Olmesartan is combined with Simeprevir.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Olmesartan is combined with Dapagliflozin.]
[C01CA27, droxidopa, Droxidopa may decrease the antihypertensive activities of Olmesartan.]
[C07AB04, acebutolol, Olmesartan may increase the hypotensive activities of Acebutolol.]
[S01ED02, betaxolol, Betaxolol may increase the hypotensive activities of Olmesartan.]
[C02CC01, bethanidine, Bethanidine may decrease the antihypertensive activities of Olmesartan.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Olmesartan is combined with Empagliflozin.]
[R03AC19, olodaterol, Olodaterol may decrease the antihypertensive activities of Olmesartan.]
[S01EE02, unoprostone, Olmesartan may increase the hypotensive activities of Unoprostone.]
[N05AA04, acepromazine, Acepromazine may decrease the antihypertensive activities of Olmesartan.]
[N06AX11, mirtazapine, Mirtazapine may decrease the antihypertensive activities of Olmesartan.]
[L01EX08, lenvatinib, The risk or severity of liver damage can be increased when Olmesartan is combined with Lenvatinib.]
[N05AX16, brexpiprazole, Brexpiprazole may decrease the antihypertensive activities of Olmesartan.]
[G02CX02, flibanserin, Flibanserin may decrease the antihypertensive activities of Olmesartan.]
[N05AX15, cariprazine, Cariprazine may decrease the antihypertensive activities of Olmesartan.]
[M02AA25, aceclofenac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Acemetacin.]
[B01AC27, selexipag, Olmesartan may increase the hypotensive activities of Selexipag.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Olmesartan.]
[M01AE16, alminoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Alminoprofen.]
[N04BC01, bromocriptine, Bromocriptine may decrease the antihypertensive activities of Olmesartan.]
[N06AA19, amineptin, Amineptine may decrease the antihypertensive activities of Olmesartan.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Olmesartan is combined with Obeticholic acid.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Olmesartan is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Olmesartan is combined with Bupivacaine.]
[C07AA19, bupranolol, Olmesartan may increase the hypotensive activities of Bupranolol.]
[N05BE01, buspirone, Buspirone may decrease the antihypertensive activities of Olmesartan.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Olmesartan is combined with Arsenic trioxide.]
[A07EC04, balsalazide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Balsalazide.]
[R03CC12, bambuterol, Bambuterol may decrease the antihypertensive activities of Olmesartan.]
[C09AA07, benazepril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Benazepril is combined with Olmesartan.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Olmesartan.]
[J05AE09, tipranavir, Olmesartan may decrease the excretion rate of Tipranavir which could result in a higher serum level.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Olmesartan.]
[C07AB07, bisoprolol, Olmesartan may increase the hypotensive activities of Bisoprolol.]
[R03AC17, bitolterol, Bitolterol may decrease the antihypertensive activities of Olmesartan.]
[J05AG03, efavirenz, Olmesartan may decrease the excretion rate of Efavirenz which could result in a higher serum level.]
[C07AA17, bopindolol, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Olmesartan is combined with Nesiritide.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Canrenone.]
[R03BA02, budesonide, Olmesartan may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Olmesartan.]
[M01AB07, bumadizone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Bumadizone.]
[J05AX18, letermovir, The risk or severity of liver damage can be increased when Olmesartan is combined with Letermovir.]
[N06AA15, butriptyline, Butriptyline may decrease the antihypertensive activities of Olmesartan.]
[C09AA01, captopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Captopril is combined with Olmesartan.]
[C07AG02, carvedilol, Olmesartan may increase the hypotensive activities of Carvedilol.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Olmesartan.]
[N03AX24, cannabidiol, Cannabidiol may decrease the antihypertensive activities of Olmesartan.]
[C07AB08, celiprolol, Olmesartan may increase the hypotensive activities of Celiprolol.]
[M01AC05, lornoxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Lornoxicam.]
[C09AA08, cilazapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Cilazapril is combined with Olmesartan.]
[A03FA08, cinitapride, Cinitapride may decrease the antihypertensive activities of Olmesartan.]
[S01ED05, carteolol, Olmesartan may increase the hypotensive activities of Carteolol.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Olmesartan.]
[J01FA09, clarithromycin, Olmesartan may decrease the excretion rate of Clarithromycin which could result in a higher serum level.]
[N06BA14, solriamfetol, Solriamfetol may decrease the antihypertensive activities of Olmesartan.]
[C09CA06, candesartan, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Olmesartan is combined with Candesartan.]
[J01DC04, cefaclor, Olmesartan may decrease the excretion rate of Cefaclor which could result in a higher serum level.]
[C03BX03, cicletanine, Olmesartan may increase the hypotensive activities of Cicletanine.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Olmesartan can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, Yohimbine may decrease the antihypertensive activities of Olmesartan.]
[N02CC07, frovatriptan, Frovatriptan may decrease the antihypertensive activities of Olmesartan.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Olmesartan.]
[N02CC06, eletriptan, Eletriptan may decrease the antihypertensive activities of Olmesartan.]
[M01AH02, rofecoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Rofecoxib.]
[C08CA16, clevidipine, The risk or severity of adverse effects can be increased when Olmesartan is combined with Clevidipine.]
[C01BD07, dronedarone, Dronedarone may decrease the antihypertensive activities of Olmesartan.]
[C02AA06, methoserpidine, Olmesartan may increase the hypotensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Olmesartan is combined with Opicapone.]
[C01CA14, dopexamine, Dopexamine may decrease the antihypertensive activities of Olmesartan.]
[M01AC04, droxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Droxicam.]
[L01EX22, selpercatinib, Selpercatinib may decrease the antihypertensive activities of Olmesartan.]
[M02AA27, dexketoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Dexketoprofen.]
[C08CA17, levamlodipine, Olmesartan may increase the hypotensive activities of Levamlodipine.]
[L01FX15, belantamab mafodotin, Olmesartan may decrease the excretion rate of Belantamab mafodotin which could result in a higher serum level.]
[L01EX23, pralsetinib, The risk or severity of liver damage can be increased when Olmesartan is combined with Pralsetinib.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Olmesartan can be increased when used in combination with Chlorothiazide.]
[N05AA01, chlorpromazine, The risk or severity of liver damage can be increased when Olmesartan is combined with Chlorpromazine.]
[C03BA04, chlorthalidone, Olmesartan may increase the hypotensive activities of Chlorthalidone.]
[N02BA07, ethenzamide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Ethenzamide.]
[N06BX18, vinpocetine, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Vinpocetine.]
[M01AB08, etodolac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Etofenamate.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Olmesartan.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Olmesartan is combined with Vericiguat.]
[M01AE05, fenbufen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Fenbufen.]
[C01CA19, fenoldopam, Olmesartan may increase the hypotensive activities of Fenoldopam.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Olmesartan.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Olmesartan.]
[S01JA01, fluorescein, Olmesartan may decrease the excretion rate of Fluorescein which could result in a higher serum level.]
[R03CC15, formoterol, Formoterol may decrease the antihypertensive activities of Olmesartan.]
[N01AB05, trichloroethylene, Trichloroethylene may decrease the antihypertensive activities of Olmesartan.]
[H04AA02, dasiglucagon, Olmesartan may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The risk or severity of liver damage can be increased when Olmesartan is combined with Cimetidine.]
[N07CA02, cinnarizine, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Cinnarizine.]
[S03AA07, ciprofloxacin, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Ciprofloxacin.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Finerenone.]
[A10BB12, glimepiride, Olmesartan may decrease the excretion rate of Glimepiride which could result in a higher serum level.]
[R03CC13, clenbuterol, Clenbuterol may decrease the antihypertensive activities of Olmesartan.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Olmesartan is combined with Levobupivacaine.]
[N06AA04, clomipramine, Clomipramine may decrease the antihypertensive activities of Olmesartan.]
[S01EA04, clonidine, The risk or severity of hypotension can be increased when Clonidine is combined with Olmesartan.]
[A05BA08, glycyrrhizic acid, Olmesartan may decrease the excretion rate of Glycyrrhizic acid which could result in a higher serum level.]
[N05AH02, clozapine, Clozapine may decrease the antihypertensive activities of Olmesartan.]
[C02KB01, metyrosine, Olmesartan may increase the hypotensive activities of Metyrosine.]
[M01AX13, proquazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Proquazone.]
[N01AB07, desflurane, Desflurane may decrease the antihypertensive activities of Olmesartan.]
[C04AX28, ifenprodil, Ifenprodil may decrease the antihypertensive activities of Olmesartan.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Imidazole salicylate.]
[B01AC10, indobufen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Indobufen.]
[M01AH03, valdecoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Valdecoxib.]
[A03AX10, isometheptene, Isometheptene may decrease the antihypertensive activities of Olmesartan.]
[N02CC05, almotriptan, Almotriptan may decrease the antihypertensive activities of Olmesartan.]
[M01AH04, parecoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Parecoxib.]
[J02AC02, itraconazole, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Bemiparin is combined with Olmesartan.]
[M01AA06, kebuzone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Kebuzone.]
[L01EA01, imatinib, Olmesartan may decrease the excretion rate of Imatinib which could result in a higher serum level.]
[S01EE04, travoprost, Olmesartan may increase the hypotensive activities of Travoprost.]
[S01EE03, bimatoprost, Olmesartan may increase the hypotensive activities of Bimatoprost.]
[C08CA09, lacidipine, Olmesartan may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Lamotrigine.]
[N07BC04, lofexidine, Lofexidine may decrease the antihypertensive activities of Olmesartan.]
[M01AB09, lonazolac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Lonazolac.]
[R06AX13, loratadine, Olmesartan may decrease the excretion rate of Loratadine which could result in a higher serum level.]
[M02AA31, loxoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Loxoprofen.]
[C09AA03, lisinopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Lisinopril is combined with Olmesartan.]
[C08CA11, manidipine, Olmesartan may increase the hypotensive activities of Manidipine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Olmesartan.]
[C07AA14, mepindolol, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Mepindolol.]
[C04AX01, cyclandelate, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Cyclandelate.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the antihypertensive activities of Olmesartan.]
[C03DA04, eplerenone, The risk or severity of hyperkalemia can be increased when Eplerenone is combined with Olmesartan.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Olmesartan can be increased when used in combination with Cyclopenthiazide.]
[N06AX07, minaprine, Minaprine may increase the hypotensive activities of Olmesartan.]
[S01XA18, cyclosporine, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Olmesartan.]
[C09AA13, moexipril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Moexipril is combined with Olmesartan.]
[M02AA02, mofebutazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Morniflumate.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Olmesartan is combined with Conivaptan.]
[C02AC05, moxonidine, Moxonidine may decrease the antihypertensive activities of Olmesartan.]
[G04BE09, vardenafil, Vardenafil may increase the antihypertensive activities of Olmesartan.]
[M01AH05, etoricoxib, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Etoricoxib.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Dantrolene.]
[L01DB02, daunorubicin, Olmesartan may decrease the excretion rate of Daunorubicin which could result in a higher serum level.]
[C02CC04, debrisoquin, Olmesartan may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Olmesartan is combined with Nabilone.]
[M01AX01, nabumetone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Nabumetone.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Olmesartan.]
[C07AB12, nebivolol, Olmesartan may increase the hypotensive activities of Nebivolol.]
[N06AX06, nefazodone, Olmesartan may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, The risk or severity of hyperkalemia can be increased when Nicorandil is combined with Olmesartan.]
[C01CA23, theodrenaline, Theodrenaline may decrease the antihypertensive activities of Olmesartan.]
[C01CA05, norfenefrine, Norfenefrine may decrease the antihypertensive activities of Olmesartan.]
[S01AA13, fusidic acid, The risk or severity of liver damage can be increased when Olmesartan is combined with Fusidic acid.]
[M01AG01, mefenamic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Mefenamic acid.]
[G04BD08, solifenacin, Solifenacin may decrease the antihypertensive activities of Olmesartan.]
[A07EC03, olsalazine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Olsalazine.]
[N06AA01, desipramine, Desipramine may decrease the antihypertensive activities of Olmesartan.]
[H01BA02, desmopressin, Desmopressin may decrease the antihypertensive activities of Olmesartan.]
[C09XA02, aliskiren, The risk or severity of hyperkalemia can be increased when Aliskiren is combined with Olmesartan.]
[M01AE12, oxaprozin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Oxaprozin.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the antihypertensive activities of Olmesartan.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Olmesartan.]
[N06AA08, dibenzepin, Dibenzepin may decrease the antihypertensive activities of Olmesartan.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Olmesartan is combined with Diclofenamide.]
[S01BC03, diclofenac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Diclofenac.]
[C02DG01, pinacidil, Olmesartan may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Olmesartan is combined with Pipamperone.]
[R03CC07, pirbuterol, Pirbuterol may decrease the antihypertensive activities of Olmesartan.]
[A08AA03, diethylpropion, Diethylpropion may decrease the antihypertensive activities of Olmesartan.]
[L02AA01, diethylstilbestrol, Olmesartan may decrease the excretion rate of Diethylstilbestrol which could result in a higher serum level.]
[C08CA03, isradipine, Olmesartan may decrease the excretion rate of Isradipine which could result in a higher serum level.]
[N02BA11, diflunisal, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Diflunisal.]
[C02DB01, dihydralazine, Olmesartan may increase the hypotensive activities of Dihydralazine.]
[C10AX09, ezetimibe, Olmesartan may decrease the excretion rate of Ezetimibe which could result in a higher serum level.]
[C04AE04, dihydroergocristine, Olmesartan may decrease the excretion rate of Dihydroergocristine which could result in a higher serum level.]
[N02CA01, dihydroergotamine, Dihydroergotamine may decrease the antihypertensive activities of Olmesartan.]
[J05AE08, atazanavir, Olmesartan may decrease the excretion rate of Atazanavir which could result in a higher serum level.]
[B01AC21, treprostinil, Treprostinil may increase the hypotensive activities of Olmesartan.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Olmesartan.]
[C08DB01, diltiazem, Olmesartan may increase the hypotensive activities of Diltiazem.]
[R03CC08, procaterol, Procaterol may decrease the antihypertensive activities of Olmesartan.]
[N02BB04, propyphenazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Proglumetacin.]
[C09AA06, quinapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Quinapril is combined with Olmesartan.]
[B01AC07, dipyridamole, Olmesartan may decrease the excretion rate of Dipyridamole which could result in a higher serum level.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Olmesartan.]
[N06AA23, quinupramine, Quinupramine may decrease the antihypertensive activities of Olmesartan.]
[C09AA05, ramipril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ramipril is combined with Olmesartan.]
[R03CC14, reproterol, Reproterol may decrease the antihypertensive activities of Olmesartan.]
[P03AA04, disulfiram, Olmesartan may decrease the excretion rate of Disulfiram which could result in a higher serum level.]
[N05AX08, risperidone, Olmesartan may increase the hypotensive activities of Risperidone.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Olmesartan is combined with Ropivacaine.]
[C03XA01, tolvaptan, The risk or severity of hyperkalemia can be increased when Tolvaptan is combined with Olmesartan.]
[G04BE08, tadalafil, Olmesartan may increase the hypotensive activities of Tadalafil.]
[S01BC05, ketorolac, The therapeutic efficacy of Olmesartan can be decreased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, Olmesartan may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, Olmesartan may decrease the excretion rate of Ranolazine which could result in a higher serum level.]
[N02BA06, salsalate, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Salsalate.]
[R03AC12, salmeterol, Salmeterol may decrease the antihypertensive activities of Olmesartan.]
[C01CA07, dobutamine, Dobutamine may decrease the antihypertensive activities of Olmesartan.]
[C01CA04, dopamine, Dopamine may decrease the antihypertensive activities of Olmesartan.]
[N06AA16, dothiepin, Dosulepin may decrease the antihypertensive activities of Olmesartan.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Olmesartan.]
[N06AA12, doxepin, Doxepin may decrease the antihypertensive activities of Olmesartan.]
[L01DB01, doxorubicin, Olmesartan may decrease the excretion rate of Doxorubicin which could result in a higher serum level.]
[N01AB08, sevoflurane, Sevoflurane may decrease the antihypertensive activities of Olmesartan.]
[N05AD08, droperidol, Droperidol may decrease the antihypertensive activities of Olmesartan.]
[C10AA01, simvastatin, Olmesartan may decrease the excretion rate of Simvastatin which could result in a higher serum level.]
[V03AG05, sodium phosphate, The risk or severity of nephrotoxicity can be increased when Olmesartan is combined with Sodium phosphate, monobasic.]
[C09AA11, spirapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Spirapril is combined with Olmesartan.]
[N02CC01, sumatriptan, Sumatriptan may decrease the antihypertensive activities of Olmesartan.]
[C07AB13, talinolol, Olmesartan may increase the hypotensive activities of Talinolol.]
[M01AC02, tenoxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Tenoxicam.]
[G04CA03, terazosin, Olmesartan may increase the hypotensive activities of Terazosin.]
[G04BD05, terodiline, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Terodiline.]
[C07AA16, tertatolol, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Tertatolol.]
[S01GA02, tetrahydrozoline, Tetryzoline may decrease the antihypertensive activities of Olmesartan.]
[N06AX14, tianeptine, Tianeptine may decrease the antihypertensive activities of Olmesartan.]
[C09AA02, enalapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Enalapril is combined with Olmesartan.]
[M01AG02, tolfenamic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Olmesartan.]
[N06BA09, atomoxetine, Atomoxetine may decrease the antihypertensive activities of Olmesartan.]
[C03CA04, torsemide, Torasemide may increase the hypotensive activities of Olmesartan.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Olmesartan.]
[C09AA10, trandolapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Trandolapril is combined with Olmesartan.]
[R03CC11, tulobuterol, Tulobuterol may decrease the antihypertensive activities of Olmesartan.]
[C02CA06, urapidil, Urapidil may decrease the antihypertensive activities of Olmesartan.]
[S01FB02, ephedrine, Ephedrine may decrease the antihypertensive activities of Olmesartan.]
[C01CX07, xamoterol, Xamoterol may decrease the antihypertensive activities of Olmesartan.]
[S01GA03, xylometazoline, Xylometazoline may decrease the antihypertensive activities of Olmesartan.]
[C08CA12, mepirodipine, Olmesartan may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, Epinephrine may decrease the antihypertensive activities of Olmesartan.]
[C09AA15, zofenopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Zofenopril is combined with Olmesartan.]
[M01AB04, zomepirac, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Zonisamide.]
[C02AC02, guanfacine, Guanfacine may decrease the antihypertensive activities of Olmesartan.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Olmesartan.]
[G02AB03, ergonovine, Ergometrine may decrease the antihypertensive activities of Olmesartan.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may decrease the antihypertensive activities of Olmesartan.]
[N02CA02, ergotamine, Ergotamine may decrease the antihypertensive activities of Olmesartan.]
[S01AA17, erythromycin, Olmesartan may decrease the excretion rate of Erythromycin which could result in a higher serum level.]
[C01CA15, gepefrine, Gepefrine may decrease the antihypertensive activities of Olmesartan.]
[L02AA03, ethinyl estradiol, The risk or severity of liver damage can be increased when Olmesartan is combined with Ethinylestradiol.]
[V03AF05, amifostine, Olmesartan may increase the hypotensive activities of Amifostine.]
[N03AD01, ethosuximide, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Ethosuximide.]
[M01AC06, meloxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Meloxicam.]
[C01CA01, etilefrine, Etilefrine may decrease the antihypertensive activities of Olmesartan.]
[N01AX07, etomidate, Etomidate may decrease the antihypertensive activities of Olmesartan.]
[L04AD02, tacrolimus, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Tacrolimus.]
[R06AX11, astemizole, Olmesartan may decrease the excretion rate of Astemizole which could result in a higher serum level.]
[R06AX12, terfenadine, Olmesartan may decrease the excretion rate of Terfenadine which could result in a higher serum level.]
[N06AB08, fluvoxamine, Olmesartan may decrease the excretion rate of Fluvoxamine which could result in a higher serum level.]
[C10AA03, pravastatin, Olmesartan may decrease the excretion rate of Pravastatin which could result in a higher serum level.]
[C08CA02, felodipine, Olmesartan may decrease the excretion rate of Felodipine which could result in a higher serum level.]
[C08EA01, fendiline, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Fendiline.]
[M01AE04, fenoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Fenoprofen.]
[R03CC04, fenoterol, Fenoterol may decrease the antihypertensive activities of Olmesartan.]
[N02AB03, fentanyl, Fentanyl may decrease the antihypertensive activities of Olmesartan.]
[R03CC02, albuterol, Salbutamol may decrease the antihypertensive activities of Olmesartan.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Olmesartan is combined with Clofarabine.]
[N02BG04, floctafenine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Floctafenine.]
[J01CF05, floxacillin, Olmesartan may decrease the excretion rate of Flucloxacillin which could result in a higher serum level.]
[J02AC01, fluconazole, The risk or severity of hyperkalemia can be increased when Fluconazole is combined with Olmesartan.]
[N07CA03, flunarizine, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Flunarizine.]
[N06AA14, melitracen, Melitracen may decrease the antihypertensive activities of Olmesartan.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Olmesartan.]
[N05AF01, flupenthixol, Flupentixol may decrease the antihypertensive activities of Olmesartan.]
[S01BC04, flurbiprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Fluspirilene.]
[N06BX17, adrafinil, Adrafinil may decrease the antihypertensive activities of Olmesartan.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Olmesartan.]
[C03CA01, furosemide, The risk or severity of renal failure and hypotension can be increased when Furosemide is combined with Olmesartan.]
[C08DA02, gallopamil, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Gallopamil.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Olmesartan.]
[N04BC06, cabergoline, Cabergoline may decrease the antihypertensive activities of Olmesartan.]
[N03AD03, methsuximide, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Methsuximide.]
[N01AH02, alfentanil, Alfentanil may decrease the antihypertensive activities of Olmesartan.]
[A10BB01, glyburide, Olmesartan may decrease the excretion rate of Glyburide which could result in a higher serum level.]
[A10BB07, glipizide, Olmesartan may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the antihypertensive activities of Olmesartan.]
[C05AE01, nitroglycerin, Olmesartan may increase the hypotensive activities of Nitroglycerin.]
[C02CA04, doxazosin, Olmesartan may increase the hypotensive activities of Doxazosin.]
[C07AB09, esmolol, Esmolol may increase the hypotensive activities of Olmesartan.]
[C09AA09, fosinopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Fosinopril is combined with Olmesartan.]
[S01EX01, guanethidine, Olmesartan may increase the hypotensive activities of Guanethidine.]
[N01AB01, halothane, Halothane may decrease the antihypertensive activities of Olmesartan.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Olmesartan.]
[C09CA01, losartan, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Olmesartan is combined with Losartan.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Heparin is combined with Olmesartan.]
[A07EC02, mesalamine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Mesalazine.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Olmesartan.]
[R03CC05, hexoprenaline, Hexoprenaline may decrease the antihypertensive activities of Olmesartan.]
[C08CA10, nilvadipine, Olmesartan may increase the hypotensive activities of Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Nimesulide.]
[C09AA04, perindopril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Perindopril is combined with Olmesartan.]
[C02DB02, hydralazine, Olmesartan may increase the hypotensive activities of Hydralazine.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Olmesartan can be increased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Olmesartan.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Olmesartan.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Olmesartan.]
[G04BD06, propiverine, Propiverine may decrease the antihypertensive activities of Olmesartan.]
[C02AC06, rilmenidine, Rilmenidine may decrease the antihypertensive activities of Olmesartan.]
[R02AX02, ibuprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Ibuprofen.]
[N01AH03, sufentanil, Sufentanil may decrease the antihypertensive activities of Olmesartan.]
[N06AA02, imipramine, Imipramine may decrease the antihypertensive activities of Olmesartan.]
[L01CD01, paclitaxel, Olmesartan may decrease the excretion rate of Paclitaxel which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Olmesartan is combined with Tizanidine.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Olmesartan.]
[S01BC01, indomethacin, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Indomethacin.]
[C02CA02, indoramin, Indoramin may decrease the antihypertensive activities of Olmesartan.]
[C10AA06, cerivastatin, Olmesartan may decrease the excretion rate of Cerivastatin which could result in a higher serum level.]
[C07AA01, alprenolol, Olmesartan may increase the hypotensive activities of Alprenolol.]
[N06AA13, iprindole, Iprindole may decrease the antihypertensive activities of Olmesartan.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Olmesartan.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Olmesartan.]
[S01EC03, dorzolamide, Olmesartan may increase the hypotensive activities of Dorzolamide.]
[R03CC06, isoetharine, Isoetharine may decrease the antihypertensive activities of Olmesartan.]
[C09AA16, imidapril, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Imidapril is combined with Olmesartan.]
[N01AB06, isoflurane, Isoflurane may decrease the antihypertensive activities of Olmesartan.]
[R03CB01, isoproterenol, Isoprenaline may decrease the antihypertensive activities of Olmesartan.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide dinitrate.]
[C04AA01, isoxsuprine, Isoxsuprine may decrease the antihypertensive activities of Olmesartan.]
[C02KD01, ketanserin, Olmesartan may increase the hypotensive activities of Ketanserin.]
[J02AB02, ketoconazole, Olmesartan may decrease the excretion rate of Ketoconazole which could result in a higher serum level.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olmesartan is combined with Olanzapine.]
[M02AA10, ketoprofen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Ketoprofen.]
[C01CA22, arbutamine, Arbutamine may decrease the antihypertensive activities of Olmesartan.]
[N04BC09, rotigotine, Rotigotine may decrease the antihypertensive activities of Olmesartan.]
[M01AE11, tiaprofenic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Tiaprofenic acid.]
[C07AG01, labetalol, Olmesartan may increase the hypotensive activities of Labetalol.]
[C02AA05, deserpidine, Olmesartan may increase the hypotensive activities of Deserpidine.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Olmesartan is combined with Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Olmesartan is combined with Levodopa.]
[C08EX01, lidoflazine, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Lidoflazine.]
[C03DB01, amiloride, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Amiloride.]
[N02CA07, lisuride, Lisuride may decrease the antihypertensive activities of Olmesartan.]
[N06AA07, lofepramine, Lofepramine may decrease the antihypertensive activities of Olmesartan.]
[A07DA03, loperamide, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Loperamide.]
[C10AA02, lovastatin, Olmesartan may decrease the excretion rate of Lovastatin which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Magnesium sulfate.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Olmesartan is combined with Mannitol.]
[C02BB01, mecamylamine, Olmesartan may increase the hypotensive activities of Mecamylamine.]
[M02AA18, meclofenamic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Meclofenamic acid.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Nadroparin is combined with Olmesartan.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Enoxaparin is combined with Olmesartan.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Dalteparin is combined with Olmesartan.]
[C01CA11, mephentermine, Mephentermine may decrease the antihypertensive activities of Olmesartan.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Olmesartan.]
[N05AX13, paliperidone, Paliperidone may decrease the antihypertensive activities of Olmesartan.]
[C01CA09, metaraminol, Metaraminol may decrease the antihypertensive activities of Olmesartan.]
[N06BA03, methamphetamine, Metamfetamine may decrease the antihypertensive activities of Olmesartan.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Olmesartan is combined with Methazolamide.]
[G02CB05, metergoline, Metergoline may decrease the antihypertensive activities of Olmesartan.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Olmesartan.]
[N05AA02, methotrimeprazine, Methotrimeprazine may decrease the antihypertensive activities of Olmesartan.]
[C01CA10, methoxamine, Methoxamine may decrease the antihypertensive activities of Olmesartan.]
[N02BG09, methoxyflurane, Methoxyflurane may decrease the antihypertensive activities of Olmesartan.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Olmesartan can be increased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, Olmesartan may increase the hypotensive activities of Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the hypotensive activities of Olmesartan.]
[G02AB01, methylergonovine, Methylergometrine may decrease the antihypertensive activities of Olmesartan.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Olmesartan.]
[N02CA04, methysergide, Methysergide may decrease the antihypertensive activities of Olmesartan.]
[C03BA08, metolazone, Olmesartan may increase the hypotensive activities of Metolazone.]
[C07AB02, metoprolol, Metoprolol may increase the hypotensive activities of Olmesartan.]
[N06AX03, mianserin, Mianserin may decrease the antihypertensive activities of Olmesartan.]
[N02BB03, aminopyrine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Aminophenazone.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Parnaparin is combined with Olmesartan.]
[C01CA17, midodrine, Midodrine may decrease the antihypertensive activities of Olmesartan.]
[G03XB01, mifepristone, Olmesartan may decrease the excretion rate of Mifepristone which could result in a higher serum level.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Tinzaparin is combined with Olmesartan.]
[C09CA03, valsartan, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Valsartan is combined with Olmesartan.]
[D11AX01, minoxidil, Olmesartan may increase the hypotensive activities of Minoxidil.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the antihypertensive activities of Olmesartan.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Olmesartan.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Olmesartan.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Olmesartan is combined with Amiodarone.]
[N06AA09, amitriptyline, Amitriptyline may decrease the antihypertensive activities of Olmesartan.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Olmesartan is combined with Morphine.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Ammonium chloride.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Olmesartan.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Olmesartan is combined with Silodosin.]
[N06AA17, amoxapine, Amoxapine may decrease the antihypertensive activities of Olmesartan.]
[C07AA12, nadolol, Olmesartan may increase the hypotensive activities of Nadolol.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Olmesartan.]
[S01GA01, naphazoline, Naphazoline may decrease the antihypertensive activities of Olmesartan.]
[N06BA01, amphetamine, Amphetamine may decrease the antihypertensive activities of Olmesartan.]
[M02AA12, naproxen, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Naproxen.]
[A10BG01, troglitazone, The risk or severity of liver damage can be increased when Troglitazone is combined with Olmesartan.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Olmesartan is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Olmesartan is combined with Tolcapone.]
[N01AH06, remifentanil, Remifentanil may decrease the antihypertensive activities of Olmesartan.]
[A10BX02, repaglinide, Olmesartan may decrease the excretion rate of Repaglinide which could result in a higher serum level.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Olmesartan is combined with Levosimendan.]
[N05AX14, iloperidone, Iloperidone may decrease the antihypertensive activities of Olmesartan.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Olmesartan is combined with Amphotericin B.]
[C09CA07, telmisartan, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Olmesartan is combined with Telmisartan.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Olmesartan.]
[C08CA04, nicardipine, Olmesartan may decrease the excretion rate of Nicardipine which could result in a higher serum level.]
[C04AE02, nicergoline, Nicergoline may decrease the antihypertensive activities of Olmesartan.]
[C08CA05, nifedipine, Olmesartan may decrease the excretion rate of Nifedipine which could result in a higher serum level.]
[M02AA17, niflumic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Olmesartan is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Olmesartan may increase the hypotensive activities of Nimodipine.]
[C08CA07, nisoldipine, Olmesartan may increase the hypotensive activities of Nisoldipine.]
[C08CA08, nitrendipine, Olmesartan may decrease the excretion rate of Nitrendipine which could result in a higher serum level.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Olmesartan is combined with Nitric Oxide.]
[J01XE01, nitrofurantoin, Olmesartan may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Olmesartan is combined with Pramipexole.]
[C02DD01, nitroprusside, Olmesartan may increase the hypotensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may decrease the antihypertensive activities of Olmesartan.]
[C01CA03, norepinephrine, Norepinephrine may decrease the antihypertensive activities of Olmesartan.]
[C02KX01, bosentan, The risk or severity of liver damage can be increased when Olmesartan is combined with Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may decrease the antihypertensive activities of Olmesartan.]
[G02CA02, nylidrin, Nylidrin may decrease the antihypertensive activities of Olmesartan.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Reviparin is combined with Olmesartan.]
[S02AA16, ofloxacin, Olmesartan may decrease the excretion rate of Ofloxacin which could result in a higher serum level.]
[N06AA05, opipramol, Opipramol may decrease the antihypertensive activities of Olmesartan.]
[R03CB03, metaproterenol, Orciprenaline may decrease the antihypertensive activities of Olmesartan.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Olmesartan is combined with Tamsulosin.]
[C07AA02, oxprenolol, Olmesartan may increase the hypotensive activities of Oxprenolol.]
[C01DX03, oxyfedrine, Oxyfedrine may decrease the antihypertensive activities of Olmesartan.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Olmesartan can be decreased when used in combination with Oxymetazoline.]
[S01BC02, oxyphenbutazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Oxyphenbutazone.]
[N05AH05, asenapine, Asenapine may decrease the antihypertensive activities of Olmesartan.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Danaparoid is combined with Olmesartan.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Olmesartan is combined with Papaverine.]
[C02KC01, pargyline, Pargyline may increase the hypotensive activities of Olmesartan.]
[C07AA23, penbutolol, Olmesartan may increase the hypotensive activities of Penbutolol.]
[N05AG03, penfluridol, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Penfluridol.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Olmesartan.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Olmesartan.]
[N04BC02, pergolide, Pergolide may decrease the antihypertensive activities of Olmesartan.]
[C08EX02, perhexiline, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Perhexiline.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Olmesartan.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Olmesartan.]
[C04AX02, phenoxybenzamine, Phenoxybenzamine may decrease the antihypertensive activities of Olmesartan.]
[A08AA01, phentermine, Phentermine may decrease the antihypertensive activities of Olmesartan.]
[V03AB36, phentolamine, Phentolamine may decrease the antihypertensive activities of Olmesartan.]
[M02AA01, phenylbutazone, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Phenylbutazone.]
[S01GA05, phenylephrine, Phenylephrine may decrease the antihypertensive activities of Olmesartan.]
[R01BA01, phenylpropanolamine, Phenylpropanolamine may decrease the antihypertensive activities of Olmesartan.]
[C08CX01, mibefradil, Olmesartan may increase the hypotensive activities of Mibefradil.]
[C07AA03, pindolol, Olmesartan may increase the hypotensive activities of Pindolol.]
[C10AA05, atorvastatin, Olmesartan may decrease the excretion rate of Atorvastatin which could result in a higher serum level.]
[J05AE01, saquinavir, Olmesartan may decrease the excretion rate of Saquinavir which could result in a higher serum level.]
[C09CA02, eprosartan, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Olmesartan is combined with Eprosartan.]
[S01BC06, piroxicam, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Piroxicam.]
[N02CX01, pizotyline, Pizotifen may decrease the antihypertensive activities of Olmesartan.]
[C09CA04, irbesartan, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Olmesartan is combined with Irbesartan.]
[A10BG02, rosiglitazone, Olmesartan may decrease the excretion rate of Rosiglitazone which could result in a higher serum level.]
[C03AA05, polythiazide, The therapeutic efficacy of Olmesartan can be increased when used in combination with Polythiazide.]
[J05AE03, ritonavir, Olmesartan may decrease the excretion rate of Ritonavir which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Olmesartan.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Olmesartan.]
[C10AA08, pitavastatin, Olmesartan may decrease the excretion rate of Pitavastatin which could result in a higher serum level.]
[C07AB01, practolol, Olmesartan may increase the hypotensive activities of Practolol.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Olmesartan.]
[C01DX02, prenylamine, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Prenylamine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Olmesartan.]
[S01HA05, procaine, Procaine may increase the hypotensive activities of Olmesartan.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Olmesartan.]
[C10AB05, fenofibrate, Olmesartan may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[G03DA04, progesterone, The risk or severity of liver damage can be increased when Olmesartan is combined with Progesterone.]
[N05AA03, promazine, Promazine may decrease the antihypertensive activities of Olmesartan.]
[C01BC03, propafenone, Propafenone may decrease the antihypertensive activities of Olmesartan.]
[N05AC01, periciazine, Periciazine may decrease the antihypertensive activities of Olmesartan.]
[N05CM06, propiomazine, Propiomazine may decrease the antihypertensive activities of Olmesartan.]
[N01AX10, propofol, Propofol may decrease the antihypertensive activities of Olmesartan.]
[C07AA05, propranolol, Olmesartan may increase the hypotensive activities of Propranolol.]
[N02CC04, rizatriptan, Rizatriptan may decrease the antihypertensive activities of Olmesartan.]
[B01AC09, epoprostenol, Epoprostenol may increase the hypotensive activities of Olmesartan.]
[N06AA11, protriptyline, Protriptyline may decrease the antihypertensive activities of Olmesartan.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the antihypertensive activities of Olmesartan.]
[N05AX12, aripiprazole, The risk or severity of hypotension can be increased when Aripiprazole is combined with Olmesartan.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Olmesartan.]
[C01BA01, quinidine, The risk or severity of liver damage can be increased when Olmesartan is combined with Quinidine.]
[P01BC01, quinine, Quinine may increase the hypotensive activities of Olmesartan.]
[C02AA01, rescinnamine, The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Rescinnamine is combined with Olmesartan.]
[C02AA02, reserpine, The risk or severity of liver damage can be increased when Reserpine is combined with Olmesartan.]
[J04AB02, rifampin, The risk or severity of liver damage can be increased when Olmesartan is combined with Rifampicin.]
[R03AC05, rimiterol, Rimiterol may decrease the antihypertensive activities of Olmesartan.]
[G02CA01, ritodrine, Ritodrine may decrease the antihypertensive activities of Olmesartan.]
[N02BA05, salicylamide, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Salicylic acid.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Olmesartan.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Olmesartan.]
[L01FA03, obinutuzumab, Olmesartan may increase the hypotensive activities of Obinutuzumab.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Olmesartan is combined with Sotalol.]
[C03DA01, spironolactone, The risk or severity of hyperkalemia can be increased when Olmesartan is combined with Spironolactone.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide mononitrate.]
[A05AA02, ursodiol, Olmesartan may decrease the excretion rate of Ursodeoxycholic acid which could result in a higher serum level.]
